Stock on Demand This Week: Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLS) saw a downside of -1.35% to close Friday at $0.68 after subtracting -$0.01 on the day. The 5-day average trading volume is 824,400 shares of the company’s common stock. It has gained $0.7499 in the past week and touched a new high 1 time within the past 5 days. An average of 816,220 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 820,998.

RGLS’s 1-month performance is -15.56% or -$0.1255 on its low of $0.6680 reached on 10/01/21. The company’s shares have touched a 52-week low of $0.45 and high of $2.32, with the stock’s rally to the 52-week high happening on 03/12/21. YTD, RGLS has lost -49.53% or -$0.6687 and has reached a new high 9 times. However, the current price is down -70.63%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On May 17, 138 days have gone by since the last insider trading activity for Regulus Therapeutics Inc. (RGLS). Hagan Joseph P (President and CEO) most recently sold 4,186 shares at $0.89 per share on May 17. This transaction cost the insider $3,726. Sr. VP & General Counsel, Aker Christopher Ray, sold 860 shares at a price of $0.89 on May 17. Then, on Feb 16, Sr. VP & General Counsel Aker Christopher Ray sold 828 shares at a price of $1.72 per share. This transaction amounted to $1,424.

Valuation Metrics

Regulus Therapeutics Inc. (RGLS) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects. RGLS stock has a beta of 2.21. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.06 while the price-to-book (PB) in the most recent quarter is 1.42.

Regulus Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.60, with the current ratio over the same period at 4.60 meaning that RGLS stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.13The trailing 12-month EBITDA margin is -136.80%. The firm’s gross profit as reported stood at $24.16 million against revenue of $10.01 million.

The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Regulus Therapeutics Inc.’s return on assets over the past 12 months stands at -38.60%. Return on investment over the past year is -46.10%, while its return on equity (ROE) trailing 12 months is -61.00%. In comparison, the average ROE for the broader industry over the past year is -36.91.

Earnings Surprise

For the quarterly period ending June 29 this year, Analysts expected RGLS to announce -$0.08 per share in earnings in its latest quarter, but it posted -$0.08, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$6.59 million. RGLS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 12.69 million, with total debt at $9.21 million. Shareholders hold equity totaling $87.04 million

Technical Picture

Let’s look briefly at Regulus Therapeutics Inc. (RGLS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 37.25% to suggest the stock is trending Neutral, with historical volatility in this time period at 30.13%.

The stock’s 5-day moving average is $0.7005, reflecting a -7.65% or -$0.0564 change from its current price. RGLS is currently trading -19.38% above its 20-day SMA, -20.46% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -6.99% and -39.17% respectively.

Stochastic %K and %D was 8.68% and 10.95% and the average true range (ATR) pointed at 0.0443. The RSI (14) points at 41.86%, while the 14-day stochastic is at 9.93% with the period’s ATR at 0.0473. The stock’s 9-day MACD Oscillator is pointing at -0.0254 and -0.0301 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Regulus Therapeutics Inc. (NASDAQ: RGLS), B. Riley FBR Inc. launched coverage with a Neutral rating. Analysts offering their rating for RGLS stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate RGLS as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.

What is RGLS’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $0.50 and a high of $2.00, with their median price target at $1.50. Looking at these predictions, the average price target given by analysts is for Regulus Therapeutics Inc. (RGLS) stock is $1.38.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam